small molecule

FERRIPROX

DEFERIPRONE

Loss of exclusivityOctober 2038latest FDA-listed patent expiry
CompanyChiesi Usa, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameFERRIPROX
Active ingredientDEFERIPRONE
Strength1GM
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusRX

Listed patents

PatentExpiresType
11723874October 2038use U-3083
11357731October 2038use U-3083
10940115October 2038product
10780055October 2038product
11458103October 2038product
10940116October 2038product

Regulatory exclusivity

CodeExpires
ODE-417April 2028
ODE-420April 2028
ODE-421April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.